Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE: WST ) with a Overweight and raises the price target from $350 to $390.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.